Therefore, even though in our case the biopsy suggested adenocarcinoma
, after resection and complex assessment of the surgical specimen a final diagnosis of mixed adenoneuroendocrine tumor was made.
Histologically, an invasive colonic type, low grade adenocarcinoma
of the appendix (Figure 1), infiltrating up to subserosa was noted.
In this case report, we describe the classical morphologic features of a pulmonary papillary adenocarcinoma
which resemble those of papillary thyroid carcinoma and discuss the utility of immunohistochemical staining in distinguishing primary from metastatic tumours.
Primary mucinous adenocarcinoma
can arise throughout the body, the most common sites being the head and the neck.
The training set resulted in a 50-gene index that identified low-risk and high-risk stage I lung adenocarcinoma
subgroups that differed substantially with respect to survival and that was validated in the independent set.
Presently, routine testing for HER-2 protein overexpression in gastric or oesophageal adenocarcinoma
does not occur in Ghana.
In this study, we aimed to identify and characterize differentially expressed lncRNAs in lung adenocarcinoma
. TCGA analysis showed that SNHG3 was significantly upregulated in lung adenocarcinoma
Histology showed anal adenocarcinoma
with mucosecreting component and independent cells (Figure 2).
Histologic findings were those of a carcinosarcoma with endometrioid adenocarcinoma
(20%), hepatoid adenocarcinoma
(20%), and sarcomatous components consisting of chondroid (10%) and spindle cell components (50%) [Figure 4].
Material and Methods: All specimens of adenocarcinoma
prostate diagnosed at Armed forces institute of pathology on the basis of immunohistochemistry and routine histopathology irrespective of age of patient, histological type or grade of the tumor were analyzed.
Henrikson, Ph.D., M.P.H., from the Kaiser Permanente Washington Health Research Institute in Seattle, and colleagues conducted a systematic review of the benefits and harms of screening for pancreatic adenocarcinoma
to inform the USPSTF.
Just like in Her2/neu positive breast cancer, Trastuzumab (Herceptin) is also effective in Her2-positive gastric adenocarcinoma
and is approved, in combination with chemotherapy, in the international phase III Trastuzumab for Gastric Cancer (ToGA) trial.5 It can be continued as monotherapy in patients with chemotherapeutic adverse reactions.3 The frequency of HER2-positive gastric cancer varies from 6% to 29.5%.3 The status of HER2/neu expression can be evaluated both on endoscopic biopsies or resection specimens using immunohistochemistory (IHC) or fluorescence in situ hybridisation (FISH).3 The current study was planned to determine HER/neu overexpression in gastric adenocarcinomas
using IHC in a tertiary care setup.